Phenix

FIXX FRAUD: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, April 18, 2022
News, Steve Berman (lawyer), NASDAQ, GLOBE, Program, Patient, Fraud, SAN, Social media, Company, Complaint, Phenix, SEC, Person, FDA, Risk, Leibniz Centre for Tropical Marine Research, Tobacco, Pharmaceutical industry

SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FAT, Cano, Vertiv, and Homology and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 18, 2022
News, CEO, Medicare, Letter, Awareness, Weeping Angel, Ponderosa and Bonanza Steakhouses, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, PKU, Liver function tests, Food, CANO, Program, GLOBE, Patient, COO, VRT, FAT, Lists of diseases, Lists of schools in England, Defendant, Social media, Company, Complaint, Phenix, NYSE, Phenylketonuria, Sailor, ASC, Face, Risk, Alfred Wegener Institute for Polar and Marine Research, Fatburger, P.C, Pharmaceutical industry, Risk management, Audit, Vertiv, Q4, Homology, Andrew Wiederhorn, Time (disambiguation)

The class action focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Key Points: 
  • The class action focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • FAT Brands is the subject of a report published by the Los Angeles Times on February 19, 2022.
  • On this news, FAT Brands' stock fell $2.42, or 22.9%, to close at $8.14 per share on February 22, 2022, thereby injuring investors.
  • For more information on the Homology class action go to: https://bespc.com/cases/FIXX
    About Bragar Eagel & Squire, P.C.

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Friday, April 15, 2022
News, Letter, Awareness, Ext, LLP, Central District, NASDAQ, PKU, Food, Court, GLOBE, Company, Program, Patient, Securities Exchange Act of 1934, Person, Lists of diseases, Lists of schools in England, Social media, Pomerantz, Phenix, District court, Complaint, Phenylketonuria, Sailor, Lists of action films, Risk, Leibniz Centre for Tropical Marine Research, SEC Rule 10b-5, Pharmaceutical industry

NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

FIXX Stock Alert: Robbins LLP Reminds Investors of Class Action Against Homology Medicines, Inc. (FIXX)

Retrieved on: 
Thursday, April 14, 2022
Steps, News, Letter, NASDAQ, PKU, Food, Patient, Securities Exchange Act of 1934, Person, Company, Complaint, Phenix, Drug, Phenylketonuria, FDA, Risk, Pharmaceutical industry

The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, for violations of the Securities Exchange Act of 1934.
  • Homology is a genetic medicines company that focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The Company's lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults.
  • If you would like more information about Homology Medicines, Inc.'s misconduct, click here .

FIXX Stock News: Robbins LLP Investigates Homology Medicines, Inc. (FIXX) for Shareholders

Retrieved on: 
Tuesday, April 12, 2022
Legal, Professional Services, Steps, News, Letter, NASDAQ, PKU, Food, Patient, Company, Phenix, Phenylketonuria, FDA, Risk, Pharmaceutical industry

Homology is a genetic medicines company that focuses on transforming the lives of patients suffering from rare genetic diseases.

Key Points: 
  • Homology is a genetic medicines company that focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The Company's lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults.
  • If you would like more information about our investigation of Homology Medicines, Inc.'s misconduct, click here .
  • Next Steps: If you acquired shares of Homology Medicines, Inc. (FIXX) between June 10, 2019 and February 18, 2022, you have legal options.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Homology and Lucid and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 12, 2022
Company, Risk, Letter, PKU, NASDAQ, Phenix, Alfred Wegener Institute for Polar and Marine Research, Sailor, Liver function tests, Phenylketonuria, Program, Lists of schools in England, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, News, Awareness, Social media, Patient, Pharmaceutical industry, Animal, Audit, Lucid, P.C, Homology

Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.

Key Points: 
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • For more information on the Lucid class action go to: https://bespc.com/cases/LCID
    About Bragar Eagel & Squire, P.C.

FIXX CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed

Retrieved on: 
Monday, April 11, 2022
Company, Risk, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Fraud, Steve Berman (lawyer), SEC, Program, Person, GLOBE, News, Complaint, SAN, FDA, Social media, Patient, Pharmaceutical industry, Tobacco

SAN FRANCISCO, April 11, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 11, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, LLP, Letter, PKU, Central District, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Complaint, Sailor, Lists of action films, Pomerantz, District court, Phenylketonuria, Program, Court, Lists of schools in England, Food, Lists of diseases, Securities Exchange Act of 1934, Person, GLOBE, News, Ext, Awareness, SEC Rule 10b-5, Social media, Patient, Pharmaceutical industry, Animal

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, Advertising, Letter, Central District, PKU, NASDAQ, NEW, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, Investment, District court, Patient, Phenylketonuria, Program, Court, Lists of schools in England, Food, Securities Exchange Act of 1934, GLOBE, Lists of action films, News, Labour government, Awareness, FDA, Social media, The Legal 500, Pharmaceutical industry, Animal, Security (finance)

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Embark, Homology, and Lucid and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, Letter, PKU, NASDAQ, State, Phenix, Alfred Wegener Institute for Polar and Marine Research, Sailor, Liver function tests, Phenylketonuria, Program, Lists of schools in England, Food, Combination, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, Bear's Cave (Erpfingen), GLOBE, Business architecture, News, Awareness, Social media, Technology, Acquisition, Patient, Bears' Cave, Financial services, Renewable energy, Audit, Pharmaceutical industry, Animal, Lucid, P.C, Homology

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.

Key Points: 
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • On January 6, 2022, The Bear Cave published a short report entitled Problems at Embark Technology (EMBK) (the Bear Cave Report).
  • On this news, Embarks stock price fell $1.37 per share, or 16.75%, to close at $6.81 per share on January 6, 2022.
  • For more information on the Lucid class action go to: https://bespc.com/cases/LCID
    About Bragar Eagel & Squire, P.C.